Showing 2491-2500 of 9159 results for "".
Epidermal Inclusion Cysts: Dr. Goldman
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/epidermal-inclusion-cysts-dr-goldman/32687/Mitchel Goldman, MD, who took part in the "Neuromodulator and Dermal Filler" panel at Maui Derm 2025, talks about a new treatment for epidermal inclusion cysts, involving sclerotherapy medication.Neuromodulators and Dermal Fillers: Dr. Gold
https://reachmd.com/programs/practical-dermatology/neuromodulators-and-dermal-fillers-dr-gold/32694/Michael Gold, MD, talks about the new neurotoxins and applications, as well as fillers, that he covered during "Neuromodulators and Dermal Fillers: What's New, What's Coming and What Are We Doing That's New in 2025" at Maui Derm 2025.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Journal Club: Updated Clinical Practice Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-updated-clinical-practice-guidelines/32316/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with new Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, about the updated clinical practice guidelines for atopic dermatitis published in the Journal of Dermatology in December.Saeki H, et alImproving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Chronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.How to Combine Injectables with Light- and Energy-Based Devices
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-combine-injectables-with-light-and-energy-based-devices/20238/Beverly Hills cosmetic dermatologist Ava Shamban, MD, shares her expertise on using hyaluronic acid on the lateral side of the face to help fight “filler fatigue” in patients. “You can see it in the before and afters because of that glide plane lateral to the line of ligaments.”Dermatology Innovations
https://practicaldermatology.com/topics/psoriasis/dermatology-innovations/20044/From topical therapies to JAK inhibitors, there are many new drugs available to treat a wide variety of dermatologic conditions. Neal Bhatia, MD reviews what's new for atopic dermatitis, alopecia areata, scabies, lice, onychomycosis, and more. Plus, he discusses the importance of new delivery systemFive easy ways to increase your clickthrough rate
https://practicaldermatology.com/topics/practice-management/five-easy-ways-to-increase-your-clickthrough-rate/19956/Your dermatology website’s placement on the Google search results page is important – but it is not everything. Check out this short video from Ekwa Marketing to discover a few simple ways to improve traffic, no matter where your link is on the search page.DermWireTV: 2020 in Review
https://practicaldermatology.com/topics/psoriasis/dermwiretv-2020-in-review/19882/Crisaborole ointment became the first and only steroid-free, topical prescription medication for mild to moderate AD in patients as young as three months of age. Ustekinumab is approved for pediatric patients with moderate to severe plaque psoriasis. FDA approved ixekizumab injection, 80mg/mL for t